About Taysha Gene Therapies Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://tayshagtx.com/
Frequently Asked Questions
What is the 52-week range for TSHA?
The 52-week high is $7.3 and the 52-week low is $3.1.
What is the P/E ratio for TSHA?
The P/E ratio data is currently unavailable.
What is the dividend yield for TSHA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -56.19%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -780.33%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.10.
Analyst Recommendation Trends
Wall Street analyst consensus for TSHA over the last few months:
Latest TSHA News
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees restricted stock units (RSUs) representing 384,000 shares of the Company’s common stoc
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations supporting its TSHA-102 program in clinical evaluation for Rett syndrome at the 55th Child Neurology Society Annual Meeting, taking place in Montréal, Québec, Canada,
Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meeting
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the
Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform rating.
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and execution for TSHA-102. See why TSHA stock is a buy.
These 3 Risky Stocks Could Be Sitting on 100% Upside
Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-10 | Nagendran Sukumar | -200,000 | $6.24 | $1,248,000 |
| 2026-06-01 | Long Alison S | +42,671 | - | - |
| 2026-06-01 | Long Alison S | +21,335 | - | - |
| 2026-06-01 | Sepp-Lorenzino Laura | +42,671 | - | - |
| 2026-06-01 | Sepp-Lorenzino Laura | +21,335 | - | - |
| 2026-06-01 | Stalfort John A III | +42,671 | - | - |
| 2026-06-01 | Stalfort John A III | +21,335 | - | - |
| 2026-06-01 | Donenberg Phillip B. | +42,671 | - | - |
| 2026-06-01 | Donenberg Phillip B. | +21,335 | - | - |
| 2026-04-10 | Nagendran Sukumar | -19,021 | - | - |
| 2026-04-10 | Nagendran Sukumar | -200,000 | $4.46 | $892,000 |
| 2026-04-10 | Nagendran Sukumar | +19,021 | $1.71 | $32,526 |
| 2026-02-04 | Alam Kamran | -1,655 | $4.52 | $7,481 |
| 2026-01-26 | Alam Kamran | -23,849 | $4.61 | $109,944 |
| 2026-01-26 | Nagendran Sukumar | -26,918 | $4.61 | $124,092 |
| 2026-01-26 | Nolan Sean P. | -41,312 | $4.61 | $190,448 |
| 2026-01-23 | Alam Kamran | -78,968 | $4.75 | $375,098 |
| 2026-01-23 | Nagendran Sukumar | -89,132 | $4.75 | $423,377 |
| 2026-01-23 | Nolan Sean P. | -136,789 | $4.75 | $649,748 |
| 2026-01-12 | Alam Kamran | +231,000 | - | - |
| 2026-01-12 | Alam Kamran | +359,000 | - | - |
| 2026-01-12 | Nagendran Sukumar | +274,000 | - | - |
| 2026-01-12 | Nagendran Sukumar | -88,676 | - | - |
| 2026-01-12 | Nagendran Sukumar | -111,324 | - | - |
| 2026-01-12 | Nagendran Sukumar | +427,000 | - | - |
| 2026-01-12 | Nagendran Sukumar | -200,000 | $4.71 | $942,000 |
| 2026-01-12 | Nagendran Sukumar | +88,676 | $1.71 | $151,636 |
| 2026-01-12 | Nagendran Sukumar | +111,324 | $0.6989 | $77,804 |
| 2026-01-12 | Nolan Sean P. | +648,000 | - | - |
| 2026-01-12 | Nolan Sean P. | +1,008,000 | - | - |
| 2025-12-01 | Nagendran Sukumar | -260,047 | - | - |
| 2025-12-01 | Nagendran Sukumar | -260,047 | $4.51 | $1,172,812 |
| 2025-12-01 | Nagendran Sukumar | +260,047 | $1.71 | $444,680 |
| 2025-11-28 | Nagendran Sukumar | -39,953 | - | - |
| 2025-11-28 | Nagendran Sukumar | -70,172 | - | - |
| 2025-11-28 | Nagendran Sukumar | -110,125 | $4.75 | $523,094 |
| 2025-11-28 | Nagendran Sukumar | +39,953 | $1.71 | $68,320 |
| 2025-11-28 | Nagendran Sukumar | +70,172 | $0.6989 | $49,043 |